PLSE trades 18.2% below Wall Street's consensus target of $30.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PLSE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 24, 2026, Pulse Biosciences, Inc. (PLSE) has a Wall Street consensus price target of $30.67, based on estimates from 4 covering analysts. With the stock currently trading at $25.95, this represents a potential upside of +18.2%. The company has a market capitalization of $1.80B.
Analyst price targets range from a low of $30.00 to a high of $32.00, representing a 7% spread in expectations. The median target of $30.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,2 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PLSE trades at a trailing P/E of -24.0x. Analysts expect EPS to grow -3.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
INVAInnoviva, Inc. | $1.7B | $23.55 | $37.00 | +57.1% | Buy | 6.6x | 10 |
NVCRNovoCure Limited | $1.6B | $14.13 | $33.00 | +133.5% | Buy | — | 15 |
ATECAlphatec Holdings, Inc. | $1.3B | $8.50 | $18.00 | +111.8% | Buy | 26.6x | 18 |
ANABAnaptysBio, Inc. | $2.6B | $59.43 | $73.67 | +24.0% | Buy | — | 22 |
INMDInMode Ltd. | $846M | $13.35 | $18.00 | +34.8% | Hold | 10.0x | 11 |
MDTMedtronic plc | $103.5B | $80.63 | $95.80 | +18.8% | Buy | 13.5x | 51 |
BSXBoston Scientific Corporation | $67.8B | $45.60 | $82.90 | +81.8% | Buy | 13.6x | 44 |
ABTAbbott Laboratories | $157.7B | $90.53 | $127.46 | +40.8% | Buy | 16.5x | 41 |
SYKStryker Corporation | $118.8B | $310.00 | $387.46 | +25.0% | Buy | 20.7x | 51 |
ISRGIntuitive Surgical, Inc. | $143.2B | $403.18 | $597.78 | +48.3% | Buy | 38.6x | 55 |
Quick answers to the most common questions about buying PLSE stock.
Pulse Biosciences, Inc. (PLSE) has a consensus 12-month price target of $30.67, implying 18.2% upside from $25.95. The 4 analysts covering PLSE see moderate appreciation potential.
PLSE has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is mixed, with 2 Hold ratings making up the largest segment. The consensus 12-month price target of $30.67 implies 18.2% upside from current levels.
PLSE's current price is $25.95 with a consensus target of $30.67 (18.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $32 for PLSE, while the most conservative target is $30. The consensus of $30.67 represents the median expectation. These targets typically reflect 12-month expectations.
PLSE is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 2 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PLSE stock forecast based on 4 Wall Street analysts shows a consensus price target of $30.67, with estimates ranging from $30 (bear case) to $32 (bull case). The median consensus rating is "Buy".
Wall Street analysts are optimistic on PLSE, with a "Buy" consensus rating and $30.67 price target (18.2% upside). 2 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PLSE analyst price targets range from $30 to $32, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $30.67 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.